Flagship Pioneering has launched Flagship Origination Lab, U.K. in London. The scientific innovation firm said it is its first dedicated company creation unit outside the United States. Flagship committed an initial £100 million to the launch.
What the lab will do
The lab will conceive, test, fund, and build AI-native platform companies. Those companies will advance human and planetary health and other science and technology frontiers. The unit will operate as part of Flagship Labs.
Earlier U.K. work
Flagship has worked across the U.K. for three years. It opened a London office and signed an agreement with the U.K. government in 2023. Since then, it has launched Quotient Therapeutics and supported U.K. trials by Generate:Biomedicines.
Team and global network
Flagship expects to recruit and train an initial team of about 50 scientist-entrepreneurs and operators in the U.K. The lab will build a locally rooted company-creation ecosystem. It will link to Flagship's global network, including Pioneering Intelligence and Pioneering Medicines.
Flagship expects the initial commitment to scale through partnership. The firm aims to attract an additional £500 million. The lab will use that support to expand company creation in the U.K.